Schultz’ Controversial Approval Of Cyberonics Device Has Little Precedent
CDRH Director Dan Schultz's decision to override device and drug center review staff to approve Cyberonics' VNS Therapy neurostimulation device for treatment-resistant depression has scant precedent in recent history. All the same, he appears to have followed established FDA procedures
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
